drugset / Trial / NCT00322920
Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of topotecan when given weekly with cisplatin in patients with persistent, recurrent, or advanced stage cervical cancer. Secondary purposes are to describe the toxicity profile in patients with persistent, recurrent, or advanced stage cervical cancer treated with the combination of topotecan when given weekly with cisplatin and to determine the response rate and time to progression in patients with persistent, recurrent, or advanced stage cervical cancer treated with the combination of topotecan when given weekly with cisplatin.
Timeline
- Start
- 2005-07
- Primary completion
- —
- Completion
- —
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topotecan | Small molecule | 2 unknown | — |
| Background | Cisplatin | Other / unclassified | 50 mg/m2 | — |